Beth Israel Lahey Health
Beth Israel Deaconess Medical Center

Department / Committee:	**IBC Committee**
Institution:	BIDMC, Boston Campus
Membership Present:	Alex Toker, Chair Nanette Moss, BSO Gary Schweon, Unaffiliated Community Member Peter Weller, IBC Member; Infectious Disease Deborah Barbeau, IBC Member; Employee Health Lauren Peter, IBC Member; Research Compliance Barbara Garibaldi, IBC Member; Vet Adrein Sipos, Unaffiliated Community Member Simon Dillon, IBC Member; Genomics
Date:	March 4, 2026
Meeting Place:	Zoom Meeting
Meeting Convened At:	1:00 PM
Meeting Type:	Closed
Quorum: Quorum was met (at least one half plus one of roster present) and no committee members left the meeting early.	

Item Category	*Topic*	*Discussion / Follow-Up*
	Call to Order	Quorum present for meeting.
Meeting Minutes Approval	February 4, 2026 Minutes	No issues or questions regarding these minutes from members. Presiding motioned to approve, motion second, minutes were approved.
Scheduled Business	*Hong* — 25-0054 Amendment: "Molecular, Cellular, Genetic, and Animal-based Studies of Lymphatic Pathophysiology" NIH Section: III-E	**Review/Clinical Review:** The BSO presented the risk assessment. This is a modification to add use of replication incompetent adeno-associate virus (AAV) vectors to knockdown or overexpress the genes of interest, including Meis1, Pbx1, Mecom, Prox1 which are oncogenes or proto-oncogenes. The lab already has approval for work with retroviral, lentiviral and adenoviral vectors therefore they already conduct work at BL-2. The AAV vectors will be commercially obtained. AAV is considered a RG1 agent however since the transgenes are oncogenic or tumor suppressors then BSL-2 is recommended. The lab has been inspected and is in good compliance. Staff training must be confirmed prior to final approval. **Biosafety Level Approval:** **Biosafety Level-2 (BSL-2)** **Discussion:** One member noted that there is conflicting information in the protocol documents, BSL-2 and BSL-2+ are both indicated. BSO will ask them to make this correction in the documentation. **Vote to approve pending clarification on biosafety level:** For: 9 Against: 0 Abstain: 0
Scheduled Business	*Santra* — 25-0035-R Amendment: "Characterization of cell mediated responses to	**Review/Clinical Review:** The BSO presented the risk assessment. This is amendment is to receive cryopreserved PBMC from nonhuman primates (NHP) immunized with a dengue virus vaccine. They will perform T and B cell immune assays to assess cell-mediated immune responses. Tests will

	vaccination for Zika virus” NIH Section: NA	include immunological assays like IFN-g ELISpot, and flow cytometric analyses. The NHPs will not have any challenge tests with live virus. No manipulation of the Dengue virus genome will be done in the laboratory. The vaccine contains chemically attenuated dengue virus. The lab has been inspected and is in good compliance. Staff general lab training must be confirmed prior to final approval. Staff have also be provided with specific training on safe handling of NHP specimens. **Biosafety Level Approval:** **Biosafety Level-2 (BSL-2)** **Discussion:** One member asked if any testing is done to determine if there is residual virus from the live attenuated vaccine. The BSO advised that they’re waiting to hear this information back from the PI. The member asked for more information on this to help plan for any additional post-exposure testing that might be needed. **Vote to approve pending receipt of this information:** For: 9 Against: 0 Abstain: 0
Reported Incidents		No incidents to report
Adjournment		Meeting adjourned at 1:10 PM.
General	**Next meeting**	The next meeting will be held on April 1 at 1:00 PM on Zoom Meeting